Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis

Rheumatology

Volumn 47, Issue 6, 2008, Pages 877-880

  Riley, P ^a   Mccann, L J ^a   Maillard, S M ^a   Woo, P ^a   Murray, K J ^b   Pilkington, C A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

Author keywords

Anti tumour necrosis factor treatment; Calcinosis; Infliximab; Juvenile dermatomyositis; Refractory

Indexed keywords

AZATHIOPRINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; PAMIDRONIC ACID; PREDNISOLONE; STEROID;

ARTHRALGIA; ARTHRITIS; ARTICLE; CALCINOSIS; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE ACTIVITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; HUMAN; JOINT CONTRACTURE; JUVENILE DERMATOMYOSITIS; LETHARGY; MALE; MUSCLE STRENGTH; MUSCLE WEAKNESS; OSTEOPOROSIS; PRIORITY JOURNAL; RANGE OF MOTION; SKIN DISEASE; VISUAL ANALOG SCALE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CALCINOSIS; CHILD; CHILD, PRESCHOOL; DERMATOLOGIC AGENTS; DERMATOMYOSITIS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RANGE OF MOTION, ARTICULAR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44849137161     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken074     Document Type: Article

References (20)

1. Huber AM, Lang B, LeBlanc CM et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000;43:541-9.
2. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002;47:505-11.
3. Oliveri MB, Palermo R, Mautalen C, Hubscher O. Regression of calcinosis during diltiaazem treatment in juvenile dermatomyositis. J Rheumatol 1996;23:2152-5.
4. Mukamel M, Horev G, Mimouni M. New insighit into calcinosis of juvenile dermatomyositis: A study of composition and treatment. J Pediatr 2001;138:763-6.
5. Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular jevenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
6. Maini R, Clair EWSt, Breedveld F. et al. Infliximab (chimeric anti-tomour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999,354,1932-9.
7. Brandt J, Sieper J, Braun J. Infliximab in the treatment of active and severe ankylosing spondylitis. Clin Exp Rheumatol 2002;20:S106-110.
8. Hengstman GJ, van den Hooaen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-fumor necrosis factor-alpha: long-term follow-up. Eur Neurol 2004,52:61-3.
9. Amarillo CKS. Etanercept is effective in the treatment of polymyositis/ dermyositis which is refractory to conventional therapy including steroids and other disease modifying agents. Arthritis Rheum 2000;43:S193.
10. Pachman LM, Liotta-Davis MR, Hong DK et al. TNFalpha-308A allele in juvenile dermatomyositis: Association with increased production of tumor necrosis factor alpna, disease duration, and pathologic calcifications. Arthritis Rheum 2000;43:2368-77.
11. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975,292:344-7.
12. Lovell DJ, Lindsley CB, Rennebohm RM et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): A quantitative tool for the evaluation of muscle function. The juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1999;42:2213-9.
13. Huber AM, Hicks JE, Lachenbruch PA et al. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol 2001:28:1106-11.
14. Lovell D, Ruperto N, Cuttica R et al. Comparison of safety, efficacy and pharmacokinetic for 3 and 6 mg 6 mg/kg infliximab plus methotrexate in JRA patients. Arthritis Rheum 2006;52(9 Suppl):S724.
15. Huk OL, Zukor DJ, Antoniou J, Petit A. Effect of pamidronate on the stimulation of macrophage TNF-alpha release by ultra-high-molecular-weight polyethylene particles: A role for apoptosis. J Orthop Res 2003;21:81-7.
16. Reid MB, Lannerqren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: Involvement of muscle myofilaments. Am J Respir Crit Care Mad 2002;166:479-84.
17. Reid MB, Li YP. Tumor necrosis tactor-alpha and muscle wasting: A cellular Perspective. Respir Res 2001:2:269-72.
18. Antoni C, Braun J. Side effects of anti-TNF therapy: Current knowledge. Clin Exp Rheumatol 2002;20:S152-157.
19. Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid Arthritis. Rheumatology 2003;42,1566-8.
20. Ansell BM. Juvenile dermatomyositis. J Rheumatol 1992;(Sullp 33):60-2.